Research Progress On Low Molecular Weight Heparin In The Treatment Of Severe Acute Pancreatitis

Background: Severe acute pancreatitis (SAP) is one of the commonacute abdomen. SAP is a systemic disease that can induce multiple organdysfunction, which occurs suddenly and develops rapidly. Because of thecomplicated pathogenesis of SAP, a comprehensive treatment programinvolvd. Low molecular weight heparin is currently widely used in clinical.Low molecular weight heparin is known to posses a special anti-thrombinactivity which is stronger and safer than unfrationated heparin. Medicalresearch found that in addition to low molecular weight heparinanticoagulant, inhibiting platelet aggregation, but also with changes inblood rheology, anti-inflammatory, regulation of apoptosis, regulation oflipid metabolism and so on. low molecular weight heparin can interventionin severe acute pancreatitis pathophysiological processes produce atherapeutic effect.Objective: review information about research progress on LowMolecular Weight Heparin in the Treatment of Severe Acute Pancreatitis to provide the reference for future research.Methods:“low molecular weight heparin, pancreatitis, severe acutepancreatitis” were used as keywords retrieval to retrieve articles aboutlow molecular weight heparin in the treatment of severe acute pancreatitis.Results: There are a lot of aspects of low molecular weight heparin inthe treatment of severe acute pancreatitis. Show that low molecular weightheparin maybe through the improve of microcirculation, regulateinflammation, regulate acinar cell apoptosis, regulate lipid metabolismpathways in the development of severe acute pancreatitis. Comprehensivetreatment of severe acute pancreatitis in combination of low molecularweight heparin can improve patient outcomes, reduce morbidity andmortality. Low molecular weight heparin is a simple, safe, economic andeffective method for treatment of SAP.